Overture Life's DaVitri Automated Fertility Preservation Platform Adds Brazil Regulatory Clearance
Latest market authorization supports the safety and effectiveness of DaVitri for consistent, high-quality vitrification
PALO ALTO, Calif., May 08, 2025--(BUSINESS WIRE)--Overture Life, the innovator modernizing IVF to optimize reproductive freedom, announces the launch of its DaVitri platform for fertility preservation for Brazil's in vitro fertilization (IVF) clinics after being cleared for commercial use as a class I medical device by the nation's National Health Surveillance Agency (ANVISA). This latest marketing authorization makes Brazil the sixth country in South and Central America where DaVitri can be used to automate vitrification, following another recent launch in Peru. Embryologists in the two countries now join counterparts in Panama, Chile, Dominican Republic, and Argentina in improving the quality and consistency of the delicate vitrification steps, using DaVitri to help standardize processes and, ultimately, reduce the number of IVF cycles required to have a healthy baby.
"We thank the regulators at ANVISA for their thorough review of DaVitri's technical, performance, and safety data," said Hans Gangeskar, CEO of Overture Life. "ANVISA's reputation for stringent review not only offers assurance to those in Brazil seeking to utilize IVF, but further supports our belief that widespread use of the automated DaVitri device will usher in a new era for quality, accessible reproductive healthcare."
Overture's mission is to develop and deploy cutting-edge technology to bring the largely manual, outdated approaches common in IVF into the modern era. This includes the use of AI, automation, metabolomics, and microfluidics to ensure that prospective mothers can access the same high-quality fertility care regardless of income, geography, or insurance status. In particular, the tabletop DaVitri could eventually enable vitrification at a specialist's office, making IVF easier to access anywhere in the world.
"We have been using the DaVitri system since June 2024 to automate vitrification. It increases our efficiency and makes our work more reproducible and safer for patients and physicians," said Dr. Jorge Castillo Baso, a specialist in gynecology and obstetrics and a founding partner of Ferticlinic and Fertidonors in Panama. "It improves the consistency of results and eliminates variability caused by human intervention, where errors can occur. It also frees up our embryologists' workload, allowing Ferticlinic to perform more procedures without compromising quality."
About Overture Life
Overture Life integrates engineering, reproductive medicine, and regulatory-grade validation to modernize embryology lab procedures, particularly fertility preservation and embryo handling, in ways that lower repeated cycles, increase throughput, and reduce the overall cost of IVF. With R&D in Spain and active U.S. operations, including a CLIA-licensed laboratory for non-invasive embryo selection, Overture unites robotics, analytics, and clinical rigor to deliver tools that clinics and patients can trust. The company's DaVitri platform aims to boost reliability and consistency in IVF, giving women and families worldwide more control over their fertility timelines. Overture's backers include Overwater Ventures, GV (formerly Google Ventures), Khosla Ventures, Octopus Ventures and others committed to advancing the future of fertility.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250508137244/en/
Contacts
Media Contact overture@consortpartners.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 hours ago
- Yahoo
Executive order signed to lift ban on overland supersonic flight, opening door for future Greensboro-made jet
GREENSBORO, N.C. (WGHP) — A company with ambitious goals centered on the Triad is celebrating the issuance of a presidential executive order. On Friday, Donald Trump signed an executive order to lift the FAA's ban of supersonic flights over the United States. Recently, Senators Ted Budd (R-North Carolina) and Thom Tillis (R-North Carolina) were among several lawmakers who introduced bills in the house and senate that would revise this ban. The lifting of this ban comes as Boom Supersonic, a company aiming to build a supersonic airliner, has chosen Piedmont Triad International Airport in Greensboro as the site where it will build engines for its planned Overture jet. Boom wrote in a statement that it supports repealing the ban, which the company calls outdated. Boom Supersonic did multiple test flights earlier in the year with their XB-1 jet, which broke the sound barrier without creating an audible boom. 'Legalizing supersonic flight makes a renaissance in supersonic passenger travel inevitable,' said Blake Scholl, Founder and CEO of Boom Supersonic. 'We're grateful to President Trump for his leadership—this important step allows us to accelerate development of our Overture supersonic airliner.' Boom is investing about $500 million to build Overture, a commercial supersonic jet, in Greensboro and, in January 2023, on a 62-acre site where its so-called 'Superfactory' is . The company, which plans to employ more than 1,700, also has an . Boom plans to have its first passengers in the air by 2029 and will fly more than 600 'profitable routes' to destinations worldwide with a range of 4,250 nautical miles. Boom has taken on three partners to design and build which will power the Overture, and now has partnerships with companies to provide Another partner, Dimensional Energy, is to provide which is as being made from 'renewable biomass and waste resources,' which could be corn, algae or wood products. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Business Upturn
15 hours ago
- Business Upturn
LEX Diagnostics Submits Dual Applications for FDA 510(k) Clearance and CLIA Waiver for Groundbreaking LEX VELO System
CAMBRIDGESHIRE, United Kingdom, June 06, 2025 (GLOBE NEWSWIRE) — LEX Diagnostics, a leading innovator in molecular diagnostics, has submitted dual applications to the U.S. Food and Drug Administration (FDA) seeking 510(k) clearance and CLIA waived status for its VELO system, an ultra-fast point-of-care molecular diagnostics platform designed to deliver highly sensitive PCR results for key respiratory pathogens directly from a swab sample in under ten minutes.1 The FDA submission represents a pivotal step in LEX Diagnostics' strategy and underscores the company's commitment to advancing point-of-care testing with accurate, timely, and clinically actionable results. 'This milestone reflects the strength of our R&D and clinical validation programs, as well as our broader mission to make molecular diagnostics faster, simpler, and more accessible,' said Ed Farrell, Chief Executive Officer of LEX Diagnostics. 'We believe the LEX VELO system will redefine point-of-care testing by equipping healthcare providers with lab-quality results in minutes, enabling faster clinical decisions and improved patient outcomes without compromising quality while improving workflow—an achievement that will set us apart in the marketplace.' The LEX system supports multiplex testing for key respiratory pathogens, including Influenza A, Influenza B, and COVID-19, and is engineered to deliver PCR results in six to ten minutes, easily integrating into clinical workflows across primary care settings, urgent care clinics, pharmacies, physician office laboratories and decentralized acute settings. Its proprietary cartridge-based design eliminates the need for external liquid handling, promoting ease of use and reliability. LEX recently completed clinical studies in the United States with the VELO system and the Influenza/Covid assay during the 2024/2025 respiratory season. LEX Diagnostics anticipates U.S. market clearance in late 2025 or early 2026, in alignment with expected FDA review timelines. About Lex Diagnostics LEX Diagnostics, a TTP Group Company, is a molecular diagnostics company transforming point-of-care testing through its proprietary ultra-fast thermal cycling technology. Designed to deliver lab-quality PCR results directly from a swab sample in minutes, the VELO system bridges the gap between accuracy and accessibility, empowering healthcare professionals to make informed clinical decisions faster. LEX Diagnostics is headquartered in Cambridgeshire, United Kingdom. Learn more at and follow us on LinkedIn. Forward-Looking Statements This press release contains forward-looking statements, including but not limited to, statements regarding product development, regulatory timelines, market potential, and expected outcomes. These statements are based on current assumptions and expectations that are subject to risks, uncertainties, and changes in circumstances. Actual results may differ materially from those expressed or implied in forward-looking statements due to a variety of factors, including regulatory decisions, market conditions, and operational challenges. LEX Diagnostics undertakes no obligation to update or revise any forward-looking statements made herein, except as required by law. Media Contacts LEX Diagnostics Chris Hole [email protected] Scius Communications Katja Stout+44 778 943 5990 [email protected]
Yahoo
15 hours ago
- Yahoo
Quanterix to Present at Goldman Sachs Global Healthcare Conference
BILLERICA, Mass., June 06, 2025--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that President and Chief Executive Officer Masoud Toloue will present at the Goldman Sachs 46th Annual Global Healthcare Conference in Miami, Florida on Monday, June 9th, at 1:20 p.m. ET. Quanterix will also host one-on-one meetings with institutional investors during the conference. Webcast Information The live webcast presentation can be accessed from the Investors section of the company's website at A replay of the webcast will be available for a limited period following the conference. To learn more about Quanterix, visit To learn more about Quanterix's Simoa® technology, visit About Quanterix From discovery to diagnostics, Quanterix's ultrasensitive biomarker detection is fueling breakthroughs only made possible through its unparalleled sensitivity and flexibility. The Company's Simoa® technology has delivered the gold standard for earlier biomarker detection in blood, serum or plasma, with the ability to quantify proteins that are far lower than the Level of Quantification (LoQ). Its industry-leading precision instruments, digital immunoassay technology and CLIA-certified Accelerator laboratory have supported research that advances disease understanding and management in neurology, oncology, immunology, cardiology and infectious disease. Quanterix has been a trusted partner of the scientific community for nearly two decades, powering research published in more than 3,400 peer-reviewed journals. Find additional information about the Billerica, Massachusetts-based company at or follow us on Twitter and LinkedIn. View source version on Contacts Media Contact: Marissa Klaassenmedia@ Investor Relations Contact: Joshua Youngir@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
